Search

Your search keyword '"DELL' ANNA, T"' showing total 4 results
Start Over Author "DELL' ANNA, T" Language english
4 results on '"DELL' ANNA, T"'

1. Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.

Author

Dell' Anna, T, Signorelli, M, Benedetti-Panici, P, Maggioni, A, Fossati, R, Fruscio, R, Milani, R, Bocciolone, L, Buda, A, Mangioni, C, Scambia, G, Angioli, R, Campagnutta, E, Grassi, R, and Landoni, F

Subjects
*OVARIAN cancer, *OVARIAN surgery, *RANDOMIZED controlled trials, *BLOOD transfusion, *DISEASE progression, *CONFIDENCE intervals, *CANCER patients
Abstract

Background:The role of systematic aortic and pelvic lymphadenectomy (SAPL) at second-look surgery in early stage or optimally debulked advanced ovarian cancer is unclear and never addressed by randomised studies.Methods:From January 1991 through May 2001, 308 patients with the International Federation of Gynaecology and Obstetrics stage IA-IV epithelial ovarian carcinoma were randomly assigned to undergo SAPL (n=158) or resection of bulky nodes only (n=150). Primary end point was overall survival (OS).Results:The median operating time, blood loss, percentage of patients requiring blood transfusions and hospital stay were higher in the SAPL than in the control arm (P<0.001). The median number of resected nodes and the percentage of women with nodal metastases were higher in the SAPL arm as well (44% vs 8%, P<0.001 and 24.2% vs 13.3%, P:0.02). After a median follow-up of 111 months, 171 events (i.e., recurrences or deaths) were observed, and 124 patients had died. Sites of first recurrences were similar in both arms. The adjusted risk for progression and death were not statistically different (hazard ratio (HR) for progression=1.18, 95% confidence interval (CI)=0.87-1.59; P=0.29; 5-year progression-free survival (PFS)=40.9% and 53.8%; HR for death=1.04, 95% CI=0.733-1.49; P=0.81; 5-year OS=63.5% and 67.4%, in the SAPL and in the control arm, respectively).Conclusion:SAPL in second-look surgery for advanced ovarian cancer did not improve PFS and OS. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

2. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer

Author

Francesca Galli, Nicoletta Colombo, Costantino Mangioni, Stefania Chiari, Robert Fruscio, Rodolfo Milani, Cristina Bonazzi, Annalisa Garbi, Irene Floriani, Federica Dell'Orto, Tiziana Dell'Anna, Lorenzo Ceppi, Daniela Giuliani, Silvia Corso, Fruscio, R, Ceppi, L, Corso, S, Galli, F, DELL' ANNA, T, Dell'Orto, F, Giuliani, D, Garbi, A, Chiari, S, Mangioni, C, Milani, R, Floriani, I, Colombo, N, and Bonazzi, C

Subjects
Oncology, Cancer Research, Multivariate analysis, Organoplatinum Compounds, Group B, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Stage (cooking), Ovarian Neoplasms, Univariate analysis, 030219 obstetrics & reproductive medicine, Fertility Preservation, fertility sparing surgery, Middle Aged, Combined Modality Therapy, ovarian cancer, 030220 oncology & carcinogenesis, Female, Peritoneum, Infertility, Female, Omentum, Infertility, Adult, Reoperation, medicine.medical_specialty, Ovariectomy, Hysterectomy, survival, Disease-Free Survival, 03 medical and health sciences, Salpingectomy, Internal medicine, medicine, Humans, Radical surgery, Antineoplastic Agents, Alkylating, Neoplasm Staging, Retrospective Studies, business.industry, Carcinoma, Retrospective cohort study, medicine.disease, Surgery, Clinical Study, Lymph Node Excision, Neoplasm Grading, business, Follow-Up Studies
Abstract

Background: The objective of this study is to evaluate the safety of fertility-sparing surgery (FSS) for early-stage epithelial ovarian cancer (EOC). Methods: A retrospective analysis was performed to identify patients treated for early-stage EOC and to compare the clinical outcomes of patients treated with FSS and radical surgery (RS). Results: A total of 1031 patients were treated at two Institutions, 242 with FSS (group A) and 789 with RS (group B). Median duration of follow-up was 11.9 years. At univariate analyses, FSS was associated with decreased risk of relapse (P=0.002) and of tumour-related death (P=0.001). Multivariate analysis did not confirm the independent positive role of FSS neither on relapse-free interval (RFI) nor on cancer-specific survival (CSS). Tumour grade was associated with shorter RFI (P

Published
2016

3. Quality of Care for Cervical and Endometrial Cancer Patients: The Impact of Different Techniques of Sentinel Lymph Node Mapping on Patient Satisfaction

Author

Sharon Palazzi, Cinzia Crivellaro, Francesca Vecchione, Marco Cuzzocrea, Beatrice Bussi, Federica Elisei, Daniela Giuliani, Maurizio Arosio, Elena De Ponti, Giampaolo Di Martino, Tiziana Dell'Anna, Alessandro Buda, Buda, A, Elisei, F, Palazzi, S, DE PONTI, E, Arosio, M, Vecchione, F, DELL' ANNA, T, Cuzzocrea, M, Bussi, B, Giuliani, D, DI MARTINO, G, and Crivellaro, C

Subjects
Adult, Indocyanine Green, medicine.medical_specialty, genetic structures, Sentinel lymph node, Uterine Cervical Neoplasms, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Patient satisfaction, Surgical oncology, Surveys and Questionnaires, Medicine, Humans, Quality of care, Technetium Tc 99m Aggregated Albumin, Aged, Neoplasm Staging, Quality of Health Care, Aged, 80 and over, 030219 obstetrics & reproductive medicine, business.industry, Sentinel Lymph Node Biopsy, Endometrial cancer, Middle Aged, medicine.disease, Cervical cancer staging, Surgery, Endometrial Neoplasms, Sentinel lymph node mapping, Methylene Blue, chemistry, Oncology, Patient Satisfaction, 030220 oncology & carcinogenesis, Lymph Node Excision, Female, Radiology, Neoplasm Grading, Radiopharmaceuticals, Sentinel Lymph Node, business, Indocyanine green
Abstract

Objectives: The purpose of this study was to assess the quality of care in patients who underwent sentinel lymph node (SLN) mapping for endometrial and cervical cancer staging, and evaluate the impact of different techniques on patient satisfaction, i.e. radiotracer Tc99m versus indocyanine green (ICG) or methylene blue injection. Method: Women with preoperative stage I endometrial cancer or stage I (1A2–1B1) cervical cancer who underwent surgical staging, including SLN mapping, were considered for this study. Patient satisfaction was assessed using the European Organisation for Research and Treatment of Cancer IN-PATSAT32 questionnaire. Women were classified into two groups according to the different nodal mapping techniques: intracervical preoperative injection of Tc99m nanocolloid + intraoperative blue dye (Group 1) versus intraoperative cervical injection of ICG or blue dye (Group 2). Differences in patient satisfaction scores between the groups were analyzed. Results: Of the 178 eligible women, 143 were included in the study (endometrial cancer n = 106, cervical cancer n = 37): 57 underwent SLN mapping with Tc99m and blue dye (Group 1), and 86 women were mapped intraoperatively with blue dye alone or ICG (Group 2). Analysis of IN-PATSAT32 questionnaire scores showed a higher patient satisfaction score for patients in Group 2 (p = 0.001), which was independent of the physician and surgical outcomes evaluated. The scores were statistically better for Group 2, and also in rating doctors (p = 0.0001), nurses (p = 0.006), and care and services organizations (p = 0.001). Conclusions: Cervical and endometrial cancer patients who underwent SLN mapping by ICG or blue dye perceived a better quality of care when compared with those patients who underwent the combined radiocolloid and blue dye technique.

Published
2016

4. Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial

Author

Alice Maggioni, Rosanna Grassi, Roberto Angioli, F Landoni, Robert Fruscio, T Dell' Anna, Rodolfo Milani, Elio Campagnutta, A Buda, Mauro Signorelli, Luca Bocciolone, Pierluigi Benedetti-Panici, Giovanni Scambia, Costantino Mangioni, Roberta Fossati, DELL' ANNA, T, Signorelli, M, Benedetti Panici, P, Maggioni, A, Fossati, R, Fruscio, R, Milani, R, Bocciolone, L, Buda, A, Mangioni, C, Scambia, G, Angioli, R, Campagnutta, E, Grassi, R, and Landoni, F

Subjects
Adult, Cancer Research, medicine.medical_specialty, Systematic lymphadenectomy, medicine.medical_treatment, MED/40 - GINECOLOGIA E OSTETRICIA, second-look surgery, ovarian cancer, lymphadenectomy, Carcinoma, Ovarian Epithelial, Disease-Free Survival, medicine, Carcinoma, Clinical endpoint, Humans, Neoplasms, Glandular and Epithelial, Stage (cooking), Ovarian Neoplasms, Chemotherapy, business.industry, Hazard ratio, Middle Aged, medicine.disease, Confidence interval, Surgery, Treatment Outcome, Settore MED/40 - GINECOLOGIA E OSTETRICIA, Oncology, Chemotherapy, Adjuvant, Second-Look Surgery, Disease Progression, Clinical Study, Lymph Node Excision, Lymphadenectomy, Female, Lymph Nodes, business, Ovarian cancer
Abstract

Background:The role of systematic aortic and pelvic lymphadenectomy (SAPL) at second-look surgery in early stage or optimally debulked advanced ovarian cancer is unclear and never addressed by randomised studies.Methods:From January 1991 through May 2001, 308 patients with the International Federation of Gynaecology and Obstetrics stage IA-IV epithelial ovarian carcinoma were randomly assigned to undergo SAPL (n=158) or resection of bulky nodes only (n=150). Primary end point was overall survival (OS).Results:The median operating time, blood loss, percentage of patients requiring blood transfusions and hospital stay were higher in the SAPL than in the control arm (P

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results